Why is DSM Firmenich stock sliding today?

DSM Firmenich AG stock fell 6.6% to trade at CHF 90.5 after the company’s Q3 2026 trading update, released before the open, delivered results that met analyst expectations but fell short of the elevated bar the market had priced in.

Q3 continuing-operations sales rose to €2.37 billion, up 5% on a like-for-like basis, and management raised the full-year 2026 LFL sales growth forecast to approximately 5% from its prior range of 2% to 4% — yet the adjusted EBITDA margin of 20.4% slipped marginally below the 20.5% recorded in the same quarter a year ago, weighed down by an 80 basis-point negative foreign exchange effect.

The margin shortfall versus the prior year, even if modest, reinforced concerns that currency headwinds remain a persistent drag on profitability. Compounding the disappointment, the Discontinued Operations segment — the Animal Nutrition & Health business being divested to CVC Capital Partners — posted a sharp 9% LFL sales decline in Q3, a result that clouded the otherwise constructive headline from the continuing portfolio.

The company’s €540 million share repurchase program, completed in early October, also removed a technical support that had helped underpin the stock in recent weeks.

On the broader market front, Swiss equities faced their own headwinds today, with the SMI under pressure as Swiss inflation climbed to its highest level since December 2023 — a development that complicates the Swiss National Bank’s rate path and weighed on sentiment across the local bourse.

The stock had been trading near CHF 107 on Euronext Amsterdam as recently as Monday, meaning the gap between pre-update expectations and the actual release was substantial.

In combination, a "meet but not beat" earnings update, a slight year-on-year margin erosion driven by FX, a weak discontinued segment, and a deteriorating Swiss macro backdrop converged to push shares sharply lower during today’s session, unwinding much of the pre-announcement run-up in a single trading day.